Trade Tracker: Stephanie Link buys mores Zoetis

Group 1: Healthcare Sector - The healthcare sector is highlighted as the best performing sector of the quarter, with a focus on the FDA's approval of the first GLP-1 pill from Novo [1] - Zoetis has been trading at a discount compared to Elanco since March 2021, with current trading at 19 times earnings, while Elanco trades at 23 times [2] - The total addressable market for the veterinary sector is projected to reach $100 billion by 2035, with Zoetis holding a 20% market share but facing execution challenges [4] Group 2: Company Performance - Zoetis has underperformed due to the CEO's inability to execute effectively, leading to a lower stock performance despite a favorable market [2][4] - The last three quarters have seen Zoetis meet expectations but lower future guidance, contributing to its stock struggles [3] - Piper Sandler suggests a mean reversion for Zoetis, indicating potential future rewards for supporting new product launches in 2026 and 2027 [5] Group 3: Metals and Mining - Metals, particularly gold and silver, have reached new record highs, with copper having its best year since 2009 [6] - Freeport-McMoRan is noted for its low trading multiple of 17 times earnings and a 7% free cash flow yield, making it a pure play on copper [7] - Execution issues at Freeport have affected its stock performance, while Aagasta is recognized as a better operator with significant production growth [8]